143 related articles for article (PubMed ID: 22465225)
21. [The labelling index as a prognostic marker in breast carcinoma].
Bisail M; Nieddu S; Sarobba MG; Sanna G; Milia V; Ghì MG; Farris A
Minerva Med; 1994 Apr; 85(4):141-4. PubMed ID: 8028740
[TBL] [Abstract][Full Text] [Related]
22. Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome.
Yamashita M; Ogawa T; Zhang X; Hanamura N; Kashikura Y; Takamura M; Yoneda M; Shiraishi T
Breast Cancer; 2012 Apr; 19(2):170-6. PubMed ID: 20978953
[TBL] [Abstract][Full Text] [Related]
23. COX2 overexpression is a prognostic marker for Stage III breast cancer.
Kim HS; Moon HG; Han W; Yom CK; Kim WH; Kim JH; Noh DY
Breast Cancer Res Treat; 2012 Feb; 132(1):51-9. PubMed ID: 21533532
[TBL] [Abstract][Full Text] [Related]
24. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer.
Ohi Y; Umekita Y; Yoshioka T; Souda M; Rai Y; Sagara Y; Sagara Y; Sagara Y; Tanimoto A
Histopathology; 2011 Oct; 59(4):776-80. PubMed ID: 22014057
[TBL] [Abstract][Full Text] [Related]
25. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer.
Bae YK; Kim A; Kim MK; Choi JE; Kang SH; Lee SJ
Hum Pathol; 2013 Oct; 44(10):2028-37. PubMed ID: 23684510
[TBL] [Abstract][Full Text] [Related]
26. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
[TBL] [Abstract][Full Text] [Related]
27. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
28. Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells.
Droeser RA; Obermann EC; Wolf AM; Wallner S; Wolf D; Tzankov A
Clin Breast Cancer; 2013 Aug; 13(4):264-70. PubMed ID: 23829892
[TBL] [Abstract][Full Text] [Related]
29. TIMP-1 as a tumor marker in breast cancer--an update.
Würtz SO; Schrohl AS; Mouridsen H; Brünner N
Acta Oncol; 2008; 47(4):580-90. PubMed ID: 18465326
[TBL] [Abstract][Full Text] [Related]
30. Mesenchymal stem cells inhibit breast cancer cell migration and invasion through secretion of tissue inhibitor of metalloproteinase-1 and -2.
Clarke MR; Imhoff FM; Baird SK
Mol Carcinog; 2015 Oct; 54(10):1214-9. PubMed ID: 24819588
[TBL] [Abstract][Full Text] [Related]
31. Integrin expression and survival in human breast cancer.
Berry MG; Gui GP; Wells CA; Carpenter R
Eur J Surg Oncol; 2004 Jun; 30(5):484-9. PubMed ID: 15135474
[TBL] [Abstract][Full Text] [Related]
32. Lack of prognostic significance of nm23 expression in human primary breast cancer.
Göhring UJ; Eustermann I; Becker M; Neuhaus W; Rein DT; Schöndorf T
Oncol Rep; 2002; 9(6):1205-8. PubMed ID: 12375020
[TBL] [Abstract][Full Text] [Related]
33. TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro.
Bigelow RL; Williams BJ; Carroll JL; Daves LK; Cardelli JA
Breast Cancer Res Treat; 2009 Sep; 117(1):31-44. PubMed ID: 18787947
[TBL] [Abstract][Full Text] [Related]
34. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells.
Soon PS; Kim E; Pon CK; Gill AJ; Moore K; Spillane AJ; Benn DE; Baxter RC
Endocr Relat Cancer; 2013 Feb; 20(1):1-12. PubMed ID: 23111755
[TBL] [Abstract][Full Text] [Related]
36. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.
Span PN; Lindberg RL; Manders P; Tjan-Heijnen VC; Heuvel JJ; Beex LV; Sweep CG
J Pathol; 2004 Apr; 202(4):395-402. PubMed ID: 15095266
[TBL] [Abstract][Full Text] [Related]
37. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
Mylona EE; Alexandrou PT; Giannopoulou IA; Rafailidis PI; Markaki S; Keramopoulos A; Nakopoulou LL
Cancer Detect Prev; 2006; 30(2):111-7. PubMed ID: 16632244
[TBL] [Abstract][Full Text] [Related]
38. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival.
Nakopoulou L; Tsirmpa I; Alexandrou P; Louvrou A; Ampela C; Markaki S; Davaris PS
Breast Cancer Res Treat; 2003 Jan; 77(2):145-55. PubMed ID: 12602913
[TBL] [Abstract][Full Text] [Related]
39. The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells.
Nakopoulou L; Giannopoulou I; Lazaris ACh; Alexandrou P; Tsirmpa I; Markaki S; Panayotopoulou E; Keramopoulos A
APMIS; 2003 Nov; 111(11):1027-36. PubMed ID: 14629269
[TBL] [Abstract][Full Text] [Related]
40. CD24 expression has a prognostic impact in breast carcinoma.
Athanassiadou P; Grapsa D; Gonidi M; Athanassiadou AM; Tsipis A; Patsouris E
Pathol Res Pract; 2009; 205(8):524-33. PubMed ID: 19243896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
